MARC details
000 -LEADER |
fixed length control field |
01202nam a22002897a 4500 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
IIITD |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20240118153135.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
240115b xxu||||| |||| 00| 0 eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
9780008503994 |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
IIITD |
082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER |
Classification number |
920 |
Item number |
BOU-M |
100 ## - MAIN ENTRY--PERSONAL NAME |
Personal name |
Bourla, Albert |
245 ## - TITLE STATEMENT |
Title |
Moonshot : |
Remainder of title |
inside Pfizer's nine-month race to make the impossible possible |
Statement of responsibility, etc |
by Albert Bourla |
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
Name of publisher, distributor, etc |
HarperCollins, |
Place of publication, distribution, etc |
London : |
Date of publication, distribution, etc |
©2022 |
300 ## - PHYSICAL DESCRIPTION |
Extent |
216 p. : |
Dimensions |
24 cm. |
501 ## - WITH NOTE |
With note |
Include Bibliography |
505 ## - FORMATTED CONTENTS NOTE |
Title |
Preface: Luck never comes to the unprepared |
-- |
Business NOT as usual |
-- |
What is obvious is not always right |
-- |
Thinking big makes the impossible possible |
-- |
Lightspeed |
-- |
The ultimate joy |
-- |
Past, present, future |
-- |
Manufacturing, the second miracle |
-- |
Equity : easier said than done |
-- |
Navigating a political minefield |
-- |
A beacon of hope |
-- |
The science of trust |
-- |
A pro-patient, pro-innovation agenda |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
Pfizer Inc |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
Viral vaccines |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
COVID-19 (Disease)--Prevention |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
Drug development |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
Vaccines industry |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
COVID-19 (Disease)--Vaccination |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
Biotechnology |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name as entry element |
Immunology |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Source of classification or shelving scheme |
Dewey Decimal Classification |
Koha item type |
Books |